13C-Phenylalanine and 13C-Methacetin breath test to evaluate functional capacity of hepatocyte in chronic liver disease

Digestive and Liver Disease

Volumn 32, Issue 3, 2000, Pages 226-232

  Lara Baruque, S ^a,b   Razquin, M ^a   Jimenez, I ^a   Vazquez, A ^a   Gisbert, J P ^a   Pajares, J M ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

13C Methacetin breath test; 13C Phenylalanine breath test; Child Pugh classification; Chronic liver disease; Liver tests; Quantitative liver function

Indexed keywords

4 ACETANISIDINE; CARBON 13; CARBON DIOXIDE; PHENYLALANINE; ACETAMIDE DERIVATIVE; CARBON; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; BREATH ANALYSIS; CELL FUNCTION; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DISEASE SEVERITY; FEMALE; HUMAN; LIVER CELL; LIVER DYSFUNCTION; LIVER FUNCTION; MALE; MASS SPECTROMETRY; SAFETY; TIME; CHRONIC DISEASE; COMPARATIVE STUDY; HOSPITALIZATION; LIVER DISEASE; LIVER FUNCTION TEST; METABOLISM; METHODOLOGY; MIDDLE AGED; PROGNOSIS;

ACETAMIDES; ADULT; BREATH TESTS; CARBON ISOTOPES; CHRONIC DISEASE; FEMALE; HEPATOCYTES; HUMANS; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PHENYLALANINE; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 0033624343     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Child CG, Turcotte JG. Surgery and portal hypertension. In: Child CG, editors. The liver and portal hypertension. Philadelphia: W.B. Saunders Co.; 1964. p. 50-2.
2. Tygstrup N, Vilstrup H. Diagnostic procedures in the evaluation of hepatic diseases. Functional evaluation of the hepatocyte. Lab Res Methods Biol Med 1983;7:17-41
3. Baker AL, Kotake AN, Schoeller DA. Clinical utility of breath tests for the assessment of hepatic function. Semin Liver Dis 1983;3:318-29.
4. Shaked A, Nunes FA, Olthoff KM, Lucey MR. Assessment of liver function: pre- and peritransplant evaluation. Clin Chem 1997;43:8:1539-45.
5. Molino G, Cavanna A, Avagnina P, Ballare M, Torchio M. Hepatic clearance of D-Sorbitol: a non invasive test for evaluating the functional liver plasma flow. Dig Dis Sci 1987;32:753-8.
6. Salerno F, Borroni G, Moser P, Sangiovanni A, Almasio P, Budillon G, et al. Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation. A prospective multicenter Italian study. J Hepatol 1996;25:474-80.
7. Merkel C, Gatta A, Zoli M, Bolognosi M, Angeli P, Iervese T, et al. Prognostic value of galactose elimination capacity, aminopyrine breath test, and Indocyanine Green Fractional clearance in patients with cirrhosis. Comparison with the Pugh score. Dig Dis Sci 1991;36:1197-203.
8. 14C-aminopyrine. Ann Intern Med 1975;83:632-8.
9. Skak C, Keiding S. Methodological problems in the use of indocyanine green to estimate hepatic blood flow and ICG clearance in man. Liver 1987;7:155-62.
10. Huang YS, Lee SD, Deng JF, Wu JC, Lu RH, Lin YF, et al. Measuring lidocaine metabolite-monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol 1993;19:140-7.
11. Gremse DA, A-Kader HH, Schroeder TJ, Balistreri WF. Assessment of lidocaine metabolite formation as a quantitative liver function test in children. Hepatology 1990;12:565-9.
12. 13C) Phenylalanine. Am J Physiol 1990;259:E835-43.
13. 13C) Phenylalanine oxidation as a measure of hepatocyte functional capacity in end-stage liver disease. Am J Surg 1997;173:270-3.
14. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to stimulate the likelihood of metabolic pharmacokinetic interactions. Drug interactions. Clin Pharmacokinetic 1997;3:32.
15. 13C) Methacetin breath test for evaluation of liver damage. Dig Dis Sci 1987;32:344-8.
16. 2 breath analysis as a measurement of demethylation of stable isotope labelled aminopyrine in man. Clin Chim Acta 1978;84:153-62.
17. Belsley DA. Conditioning diagnostics: Collinearity and weak data in regression. New York: John Wiley & Sons; 1991.
18. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839-43.
19. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.
20. Hehir DJ, Jenkins RL, Bistrian BR, Wagner D, Moldawer LL, Young VR, et al. Abnormal Phenylalanine hydroxylation and tyrosine oxidation in a patient with acute fulminant liver disease with correction with liver transplantation. Gastroenterology 1985;89:659-63.
21. Hereber M, Talke H, Maier KP, Gerok W. Metabolism of phenylalanine in liver diseases. Klin Wochenschr 1980;58:1189-96.
22. Desmet VJ, Gerber M, Moofnagle JH, Manns M, Seheur PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
23. Porayko MK, Wiesner RH. Management of ascites in patients with cirrhosis. What to do when diuretics fail? Postgrad Med 1992;92:156-66.
24. Uribe M, Marquez A, Garcia Ramos G, Ramos-Uribe MH, Vargas F, Villalobos A, et al. Treatment of chronic portal-systemic encephalopathy with vegetable and animal protein diets. A controlled crossover study. Dig Dis Sci 1982;27:1109-16.
25. Weber FL Jr, Bagby BS, Licate L, Kelsen SG. Effects of branched chain aminoacids on nitrogen metabolism in patients with cirrhosis. Hepatology 1990;11:942-50.